Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

BACKGROUND: Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Vernocchi, Pamela, Marini, Federico, Quagliariello, Andrea, Cerbelli, Bruna, Reddel, Sofia, Del Chierico, Federica, Di Pietro, Francesca, Giusti, Raffaele, Tomassini, Alberta, Giampaoli, Ottavia, Miccheli, Alfredo, Zizzari, Ilaria Grazia, Nuti, Marianna, Putignani, Lorenza, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998840/
https://www.ncbi.nlm.nih.gov/pubmed/32014010
http://dx.doi.org/10.1186/s12967-020-02231-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998840/
https://www.ncbi.nlm.nih.gov/pubmed/32014010
http://dx.doi.org/10.1186/s12967-020-02231-0

Ejemplares similares